NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer

Figure 3 SIRT1 expression regulates the sensitivity of HCT116 Oxa-R cells to oxaliplatin. A: MTS assay was performed to determine the IC₅₀ of oxaliplatin in HCT116-WT and HCT116 Oxa-R cells; B: HCT116 Oxa-R cells were treated with salermide (10 μM) to inhibit SIRT1 expression or CAY10602 (20 μM) to increase SIRT1 expression. Cell survival curves revealed that inhibition of SIRT1 increased the IC₅₀ of oxaliplatin in HCT116 Oxa-R cells, whereas an increase in SIRT1 expression decreased the IC₅₀; C: SynergyFinder software was used to calculate the synergy score for the combination of oxaliplatin and salermide in HCT116 Oxa-R cells (a score > 10 indicates synergy, -10 to 10 indicates additive effects, and < -10 indicates antagonism); D: Compusyn software was used to evaluate the combination index (CI) for oxaliplatin and salermide in HCT116 Oxa-R cells (CI < 1 indicates synergy, CI > 1 indicates antagonism, and CI = 1 indicates additive effects). CI: Combination index.